Vasculogenic Impotence

Inability to achieve and maintain an erection (ERECTILE DYSFUNCTION) due to defects in the arterial blood flow to the PENIS, defect in venous occlusive function allowing blood drainage (leakage) from the erectile tissue (corpus cavernosum penis), or both.

Also Known As:

Networked: 119 relevant articles (7 outcomes, 12 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1.	Erectile Dysfunction
2.	Vasculogenic Impotence
3.	Penile Induration (Peyronie's Disease)
4.	Vascular Diseases (Vascular Disease)
5.	Ulcer

Experts

1.	Aronow, Wilbert S: 5 articles (09/2010 - 02/2004)
2.	Lue, T F: 2 articles (06/2002 - 08/2001)
3.	Nunes, L: 2 articles (06/2002 - 08/2001)
4.	Alessandro, Bertaccini: 1 article (12/2010)
5.	Daniele, Aloisi: 1 article (12/2010)
6.	Debora, Marchiori: 1 article (12/2010)
7.	Ferri, Claudio: 1 article (12/2010)
8.	Giuseppe, Martorana: 1 article (12/2010)
9.	Cayan, Selahittin: 1 article (09/2008)
10.	Ahn, Mi Young: 1 article (04/2008)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Vasculogenic Impotence:

1.	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 03/22/2002 - "We have previously shown that intracavernous injection of vascular endothelial growth factor (VEGF) improved the recovery of erectile function in an arteriogenic impotence rat mode. " 06/01/2002 - "To identify genes that are affected by vascular endothelial growth factor (VEGF), as an intracavernosal injection with VEGF improved the recovery of erectile function in a rat model of arteriogenic impotence, specifically examining the three nitric oxide synthase (NOS) genes, nNOS, eNOS, and iNOS. "
2.	Radioisotopes (Radionuclides)IBA 03/01/1998 - "The radioisotope erection penogram is a noninvasive, reproductive and reliable screening test for vasculogenic impotence." 01/01/1992 - "Re: Diagnostic value of the radioisotope erection penogram for vasculogenic impotence." 07/01/1991 - "Re: Diagnostic value of the radioisotope erection penogram for vasculogenic impotence." 10/01/1990 - "Radioisotope erection penography of 113 consecutive impotent patients (41 with psychogenic and 72 with vasculogenic impotence) and 15 normal potent men were obtained. " 10/01/1990 - "Diagnostic value of the radioisotope erection penogram for vasculogenic impotence."
3.	Testosterone (Sustanon)FDA Link 02/01/2006 - "Dramatic improvement of penile venous leakage upon testosterone administration. " 01/01/1985 - "Although follicle-stimulating hormone levels were higher (p = 0.001) and penile blood pressure index levels lower (p less than 0.05) in patients with impotence, sexual function was not improved by exogenous testosterone, and vasculogenic impotence was identified in only 6% of patients. "
4.	Therapeutic UsesIBA 11/01/1993 - "Selected cases of vasculogenic impotence can be safely and effectively treated by the association of drugs which rely on different mechanisms of action, producing a pharmacologic synergism which enhances the overall therapeutic effect."
5.	Nitric Oxide Synthase (NO Synthase)IBA 06/01/2002 - "To identify genes that are affected by vascular endothelial growth factor (VEGF), as an intracavernosal injection with VEGF improved the recovery of erectile function in a rat model of arteriogenic impotence, specifically examining the three nitric oxide synthase (NOS) genes, nNOS, eNOS, and iNOS. "
6.	Follicle Stimulating Hormone (Follitropin)FDA Link 01/01/1985 - "Although follicle-stimulating hormone levels were higher (p = 0.001) and penile blood pressure index levels lower (p less than 0.05) in patients with impotence, sexual function was not improved by exogenous testosterone, and vasculogenic impotence was identified in only 6% of patients. "
7.	CreatinineIBA 08/01/1992 - "The mean urinary 11-dehydro-thromboxane B2 level of 3 patients with arteriogenic impotence was significantly greater than that of the 57 control volunteers: 2.66 +/- 0.65 versus 1.74 +/- 0.56 (plus or minus standard deviation) ng./mg. creatinine (p = 0.008). " 08/01/1992 - "The 11-dehydro-thromboxane B2 concentration in the urine was 1.83 +/- 0.58, 2.54 +/- 1.12 and 1.91 +/- 0.73 ng./mg. creatinine in the 47 normal control volunteers, 20 patients with arteriogenic impotence and 29 with arteriogenic impotence plus intracavernous injection of 20 micrograms prostaglandin E1, respectively. "
8.	11-dehydro-thromboxane B2IBA 08/01/1992 - "Our findings suggest that urinary 11-dehydro-thromboxane B2 may have an important role in the diagnosis and treatment of arteriogenic impotence." 08/01/1992 - "The change of urinary 11-dehydro-thromboxane B2 and 2,3-dinor-6-keto-prostaglandin F1 alpha in arteriogenic impotence." 08/01/1992 - "The mean urinary 11-dehydro-thromboxane B2 level of 3 patients with arteriogenic impotence was significantly greater than that of the 57 control volunteers: 2.66 +/- 0.65 versus 1.74 +/- 0.56 (plus or minus standard deviation) ng./mg. creatinine (p = 0.008). " 08/01/1992 - "For the 13 patients with arteriogenic impotence (group 3) we compared the urinary 11-dehydro-thromboxane B2 and prostaglandin F1 alpha levels before and after intracavernous injection of prostaglandin E1 by using a paired t test. " 08/01/1992 - "The 11-dehydro-thromboxane B2 concentration in the urine was 1.83 +/- 0.58, 2.54 +/- 1.12 and 1.91 +/- 0.73 ng./mg. creatinine in the 47 normal control volunteers, 20 patients with arteriogenic impotence and 29 with arteriogenic impotence plus intracavernous injection of 20 micrograms prostaglandin E1, respectively. "
9.	PapaverineIBA 09/01/1998 - "Intracavernosal entothelin levels of 33 important men with arteriogenic impotence before and after papaverine-induced penile erection were examined by using radioimmunoassay kits. " 04/01/1996 - "There was no correlation between the results obtained on IPBF and those obtained from CDI; the latter is not useful in differentiating between venogenic and arteriogenic impotence in men who have failed to have a full response to papaverine." 12/01/1991 - "From the beginning of the eighties papaverine was well established as the drug of choice for diagnosis and management of vasculogenic impotence. " 10/01/1991 - "Arteriogenic impotence falls within the first group and has been assessed with the papaverine test, simple Doppler and arteriography. " 05/01/1990 - "Penile duplex ultrasonography with papaverine injection appears to be a useful objective method to evaluate vasculogenic impotence and to correlate favorably with nocturnal penile tumescence monitoring. "
10.	Alprostadil (Muse)FDA LinkGeneric 11/01/2004 - "32 patients (median age 29 years, range 17-70 years) with either a previous Doppler US pattern of venous leakage or a clinical suspicion of venogenic impotence, underwent Doppler US after a total dose of 20 microg of PGE1. " 12/01/1999 - "We found a higher incidence of CAA among post-RRP patients with normal vascular erectile responses to PGE1 (48%) compared to men with true vasculogenic impotence post-RRP (21%). " 06/01/1995 - "In patients with arteriogenic impotence, correct pharmacological diagnosis with doses of 10, 20 and 30 micrograms of PGE1, was made in 71, 89 and 90% of patients respectively. " 06/01/1995 - "An attempt to standardize the pharmacological diagnostic screening of vasculogenic impotence with prostaglandin E1." 01/01/1993 - "Duplex Doppler scanning with high-dose prostaglandin E1 stimulation in the diagnosis of arteriogenic impotence."

Therapies and Procedures

1.	Therapeutics 12/01/2010 - "In case of suspect vasculogenic impotence, even if penile Doppler is not pathological, it would be worth performing a systemic Doppler evaluation of main arteries in order to investigate the presence of atherosclerotic finding and institute a preventive therapy for CVD." 12/01/2000 - "The introduction of new oral therapy doesn't change the rule of color Doppler US in the screening modality of the diagnosis of vasculogenic impotence. " 10/01/1994 - "To combine surgical and radiological penile vein occlusion therapy in the treatment of patients with venogenic impotence, to try to improve on the results of either treatment used separately. " 11/01/1993 - "Effectiveness and safety of multidrug intracavernous therapy for vasculogenic impotence." 12/01/1992 - "We describe our experience of surgical therapy for vasculogenic impotence, using a technique of arterialization of the deep dorsal vein. "
2.	Ligation 06/01/1990 - "In the acute study, arteriogenic impotence was induced in 6 dogs by bilateral ligation of the penile arteries just proximal to the crus of the penis. " 11/01/2003 - "The ligation and resection of the deep penile vein can be considered as an easy and effective method to treat patients of ED caused by penile venous leakage." 09/01/1995 - "Venogenic impotence can be treated by dorsal vein arterialization in combination with venous ligation." 03/01/1995 - "Penile vein ligation for venogenic impotence was performed on 15 patients between 1989 and 1992. " 03/01/1995 - "Long-term results with penile vein ligation for venogenic impotence."
3.	Injections 05/01/1993 - "We performed a retrospective analysis of 101 impotent patients using intracavernous self-injections as primary therapy for vasculogenic impotence. " 02/01/1988 - "To evaluate arteriogenic impotence, sonography and pulsed Doppler analysis combined with papaverine injections provide objective and reproducible measurements of diameter increase and blood flow of each penile artery and have the advantage of being a functional study. " 06/01/1991 - "However, some patients with vasculogenic impotence respond poorly to injections of papaverine or papaverine/phentolamine. "
4.	Limb Salvage 09/01/2010 - "Indications for lower-extremity angioplasty, preferably with stenting, or bypass surgery are incapacitating claudication interfering with work or lifestyle in patients; limb salvage in patients with limb-threatening ischemia as manifested by rest pain, nonhealing ulcers, infection, or gangrene; and vasculogenic impotence." 01/01/2007 - "Indications for lower extremity percutaneous transluminal angioplasty or bypass surgery are (1) incapacitating claudication in patients interfering with work or lifestyle; (2) limb salvage in patients with limb-threatening ischemia as manifested by rest pain, nonhealing ulcers, and/or infection or gangrene; and (3) vasculogenic impotence." 01/01/2007 - "Indications for lower extremity percutaneous transluminal angioplasty or bypass surgery are (1) incapacitating claudication in persons interfering with work or lifestyle, (2) limb salvage in persons with limb-threatening ischemia as manifested by rest pain, nonhealing ulcers, and/or infection or gangrene, and (3) vasculogenic impotence." 03/01/2005 - "Indications for lower-extremity angioplasty, preferably with stenting, or bypass surgery are 1) incapacitating claudication in persons interfering with work or lifestyle; 2) limb salvage in persons with limb-threatening ischemia as manifested by rest pain, nonhealing ulcers, and/or infection or gangrene; and 3) vasculogenic impotence. " 02/01/2004 - "Indications for lower extremity angioplasty, preferably with stenting, or bypass surgery are 1) incapacitating claudication in persons interfering with work or lifestyle; 2) limb salvage in persons with limb-threatening ischemia as manifested by rest pain, nonhealing ulcers, and/or infection or gangrene; and 3) vasculogenic impotence. "
5.	Vascular Surgical Procedures 10/21/1991 - "Vascular surgery for vasculogenic impotence." 03/01/1991 - "A multidisciplinary approach with emphasis on hemodynamic tests was used to diagnose 421 patients with arteriogenic, venogenic or mixed arteriogenic/venogenic impotence who underwent a vascular surgical procedure. " 05/01/1990 - "The role of vascular surgery in arteriogenic and combined arteriogenic and venogenic impotence." 01/01/1984 - "Neurogenic and vasculogenic impotence after aortoiliac reconstruction is an unpleasant problem in vascular surgery. "